Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.68 |
| ▸ | APEX1 | P27695 | 1/20 | 0.66 |
| ▸ | DUSP22 | Q9NRW4 | 5/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.60 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.60 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.60 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3896603 | 1.00 | LCK (0.68) | LCKAPEX1DUSP22MEN1POLB | |
| SCHEMBL3896597 | 1.00 | LCK (0.68) | LCKAPEX1DUSP22MEN1POLB | |
| SCHEMBL3904180 | 0.92 | PTPN12 (0.66) | LCKAPEX1DUSP22MEN1POLB | |
| SCHEMBL29908306 | 0.92 | LCK (0.80) | LCKAPEX1DUSP22MEN1POLB | |
| SCHEMBL3904183 | 0.92 | PTPN12 (0.66) | LCKAPEX1DUSP22MEN1POLB | |
| SCHEMBL3892654 | 0.92 | APEX1 (0.71) | LCKAPEX1DUSP22MEN1POLB | |
| SCHEMBL3892650 | 0.92 | APEX1 (0.71) | LCKAPEX1DUSP22MEN1POLB | |
| SCHEMBL3896309 | 0.90 | MEN1 (0.68) | LCKAPEX1DUSP22MEN1POLB | |
| SCHEMBL3896302 | 0.90 | MEN1 (0.68) | LCKAPEX1DUSP22MEN1POLB | |
| SCHEMBL29554356 | 0.90 | MEN1 (0.68) | LCKAPEX1DUSP22MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112500482-B | Gold glucose specific nano antibody and double-antibody sandwich ELISA (enzyme-Linked immuno sorbent assay) method thereof | 南开大学（CN） | 2023-01-13 | — | — | CN | claimed |
| US-20250312367-A1 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2025-10-09 | — | — | US | disclosed |
| CN-119798441-A | Anti-TRAIL nano antibody and application thereof | 河南大学 | 2025-04-11 | — | — | CN | disclosed |
| EP-4522628-A2 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | Adarx Pharmaceuticals, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20240124575-A1 | HUMAN CD33 ANTIBODY AND USE THEREOF | HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| US-20240076403-A1 | HER2 ANTIBODY AND APPLICATION THEREOF | HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO. LTD. (CN) | 2024-03-07 | — | — | US | disclosed |
| WO-2023220737-A2 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-4269437-A1 | PD-1 BINDING MOLECULE AND APPLICATION THEREOF | Zhejiang Nanomab Technology Center Co. Ltd. (CN) | 2023-11-01 | — | — | EP | disclosed |
| CN-116867806-A | Human CD33 antibodies and uses thereof | 先声再明医药有限公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-116829718-A | PD-1 binding molecules and uses thereof | 浙江纳米抗体技术中心有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230097398-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | ELOXX PHARMACEUTICALS LTD. (IL) | 2023-03-30 | — | — | US | disclosed |
| US-11613551-B2 | Aminoglycoside derivatives and uses thereof in treating genetic disorders | ELOXX PHARMACEUTICALS LTD. (IL) | 2023-03-28 | — | — | US | disclosed |
| CN-112500482-B | Gold glucose specific nano antibody and double-antibody sandwich ELISA (enzyme-Linked immuno sorbent assay) method thereof | 南开大学（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-112500482-B | Gold glucose specific nano antibody and double-antibody sandwich ELISA (enzyme-Linked immuno sorbent assay) method thereof | 南开大学（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-114957357-A | Aminoglycoside derivatives and their use in the treatment of genetic disorders | ELOXX制药有限公司 | 2022-08-30 | — | — | CN | disclosed |
| WO-2022171113-A1 | HUMAN CD33 ANTIBODY AND USE THEREOF | 江苏先声药业有限公司 | 2022-08-18 | — | — | WO | disclosed |
| WO-2022143552-A1 | PD-1 BINDING MOLECULE AND APPLICATION THEREOF | 浙江纳米抗体技术中心有限公司 | 2022-07-07 | — | — | WO | disclosed |
| WO-2022127889-A1 | HER2 ANTIBODY AND APPLICATION THEREOF | 江苏先声药业有限公司 | 2022-06-23 | — | — | WO | disclosed |
| CN-108350014-B | Aminoglycoside derivatives and their use in the treatment of genetic disorders | ELOXX制药有限公司 | 2022-06-10 | — | — | CN | disclosed |
| US-11306115-B2 | Aminoglycoside derivatives and uses thereof in treating genetic disorders | ELOXX PHARMACEUTICALS LTD. (IL) | 2022-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230097398-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | UPF1, IDUA, UGGT1 | LCK 4777/4885APEX1 3273/4885DUSP22 2210/4885 |
| US-11306115-B2 | Aminoglycoside derivatives and uses thereof in treating genetic disorders | UPF1, IDUA, UGGT1 | LCK 4777/4885APEX1 3273/4885DUSP22 2210/4885 |
| US-20250312367-A1 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | POLRMT, TARDBP, NSUN2 | LCK 1390/4885APEX1 1098/4885DUSP22 4220/4885 |
| US-11613551-B2 | Aminoglycoside derivatives and uses thereof in treating genetic disorders | UPF1, AARS1, NUDT21 | LCK 4774/4885APEX1 2597/4885DUSP22 3930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.